Endometrial Cancer: Toxicity Management and Treatment Persistence with Lenvatinib-Pembrolizumab

The long term safety profile of lenvatinib plus pembrolizumab requires attentive, proactive management in clinical practice. Hypertension is one of the most frequent challenges and often requires close monitoring and collaboration with primary care providers. Diarrhea and hypothyroidism also occur regularly and must be addressed early to prevent treatment interruptions.Because patients often need extended time on therapy to achieve full clinical benefit, maintaining tolerability is essential. Dose adjustments for lenvatinib are common, and temporary dose delays are frequently used until adverse events stabilize. In real world practice, clinicians may re escalate the dose once a patient is better controlled, allowing them to maintain treatment intensity. With careful monitoring, many patients can remain on therapy long enough to gain meaningful benefit.